期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Impurity Profiling of Solid Oral Drug Products to Sail through GDUFA-II Requirements 被引量:1
1
作者 Raghuram Pannala 《American Journal of Analytical Chemistry》 2018年第4期187-209,共23页
Defining impurity profile is key element to ensure safe, efficacious and quality human drugs. Impurity profiling changed/transformed drastically over the years. Guidelines, specifications and requirements are evolving... Defining impurity profile is key element to ensure safe, efficacious and quality human drugs. Impurity profiling changed/transformed drastically over the years. Guidelines, specifications and requirements are evolving. Initially impurity profiling was based on simple methods later by degradation studies, then to understand drug strength and efficacy chiral impurities and stereo isomers were included followed by residual solvents, polymorphic forms, genotoxic impurity studies. Currently, elemental impurities are the latest addition. As per the GDUFA II guidelines to improve review efficiency and reduce review cycles, data requirements have changed. Based on recent guidance and review points, Impurity profiling has significant importance in ANDA filing and to ensure approval within 10 months (first cycle approval) which is an exiling aspect for industries to enter into the generic market quickly. Hence, Impurity profile is a key aspect scientifically, regulatory wise and commercially also. This is a review article on impurity profiling of Solid oral drug substances and products as per GDUFA II requirements the reference documents for the review are ICH guidance, relevant FDA GDUFA guidance and common industry practices. 展开更多
关键词 IMPURITY Profile Degradation Stereo ISOMERS GENOTOXIC POLYMORPHIC Elemental IMPURITIES FDA gdufa II Organic IMPURITIES Inorganic IMPURITIES RTR Specifications
下载PDF
企业付费法案与仿制药产业发展 被引量:6
2
作者 Garth Boehm 姚立新 郑强 《中国新药杂志》 CAS CSCD 北大核心 2013年第2期150-158,共9页
目的:研究美国FDA如何借助企业付费的方法来应对药品生产、供应全球化和不断增长的工作量的挑战,以便提高药品可及性和缓解药品短缺。方法:根据美国FDA、国会和政府问责办公室的资料及业界报告等,分析企业付费对保证药品安全性、可及性... 目的:研究美国FDA如何借助企业付费的方法来应对药品生产、供应全球化和不断增长的工作量的挑战,以便提高药品可及性和缓解药品短缺。方法:根据美国FDA、国会和政府问责办公室的资料及业界报告等,分析企业付费对保证药品安全性、可及性和监管机构透明度方面的作用。结果:采取公开、整体性的企业付费方式,有助于加速仿制药审评、实现海内外生产设施检查频率一致、保障药品的可及性和安全性及增加监管透明度。结论:仿制药企业付费法案对推动政企合作,合理利用企业资源,解决监管机构、产业界和利益攸关方共同面对的棘手问题,推动全球化时代药品监管方式的转变,提供了一条可行的途径。 展开更多
关键词 仿制药 企业付费 仿制药企业付费 GMP检查 加速审评 全球化监管 透明度
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部